These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19255346)

  • 1. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms.
    Lombardi R; Rodriguez G; Chen SN; Ripplinger CM; Li W; Chen J; Willerson JT; Betocchi S; Wickline SA; Efimov IR; Marian AJ
    Circulation; 2009 Mar; 119(10):1398-407. PubMed ID: 19255346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy.
    Senthil V; Chen SN; Tsybouleva N; Halder T; Nagueh SF; Willerson JT; Roberts R; Marian AJ
    Circ Res; 2005 Aug; 97(3):285-92. PubMed ID: 16020756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study.
    Marian AJ; Tan Y; Li L; Chang J; Syrris P; Hessabi M; Rahbar MH; Willerson JT; Cheong BY; Liu CY; Kleiman NS; Bluemke DA; Nagueh SF
    Circ Res; 2018 Apr; 122(8):1109-1118. PubMed ID: 29540445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy.
    Nagueh SF; Chen S; Patel R; Tsybouleva N; Lutucuta S; Kopelen HA; Zoghbi WA; Quiñones MA; Roberts R; Marian AJ
    J Mol Cell Cardiol; 2004 May; 36(5):663-73. PubMed ID: 15135661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.
    Patel R; Nagueh SF; Tsybouleva N; Abdellatif M; Lutucuta S; Kopelen HA; Quinones MA; Zoghbi WA; Entman ML; Roberts R; Marian AJ
    Circulation; 2001 Jul; 104(3):317-24. PubMed ID: 11457751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation.
    Marian AJ; Senthil V; Chen SN; Lombardi R
    J Am Coll Cardiol; 2006 Feb; 47(4):827-34. PubMed ID: 16487852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental therapies in hypertrophic cardiomyopathy.
    Marian AJ
    J Cardiovasc Transl Res; 2009 Dec; 2(4):483-92. PubMed ID: 20560006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy.
    Nagueh SF; Kopelen HA; Lim DS; Zoghbi WA; Quiñones MA; Roberts R; Marian AJ
    Circulation; 2000 Sep; 102(12):1346-50. PubMed ID: 10993850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
    Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
    Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
    Tsybouleva N; Zhang L; Chen S; Patel R; Lutucuta S; Nemoto S; DeFreitas G; Entman M; Carabello BA; Roberts R; Marian AJ
    Circulation; 2004 Mar; 109(10):1284-91. PubMed ID: 14993121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking cardiac growth in hypertrophic cardiomyopathy induces cardiac dysfunction and decreased survival only in males.
    Luckey SW; Mansoori J; Fair K; Antos CL; Olson EN; Leinwand LA
    Am J Physiol Heart Circ Physiol; 2007 Feb; 292(2):H838-45. PubMed ID: 17012357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity.
    Ruggiero A; Chen SN; Lombardi R; Rodriguez G; Marian AJ
    Cardiovasc Res; 2013 Jan; 97(1):44-54. PubMed ID: 22987565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Murine Hypertrophic Cardiomyopathy Model: The DBA/2J Strain.
    Zhao W; Zhao T; Chen Y; Zhao F; Gu Q; Williams RW; Bhattacharya SK; Lu L; Sun Y
    PLoS One; 2015; 10(8):e0133132. PubMed ID: 26241864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Acetylcysteine Influence on Oxidative Stress and Cardiac Remodeling in Rats During Transition from Compensated Left Ventricular Hypertrophy to Heart Failure.
    Reyes DRA; Gomes MJ; Rosa CM; Pagan LU; Damatto FC; Damatto RL; Depra I; Campos DHS; Fernandez AAH; Martinez PF; Okoshi K; Okoshi MP
    Cell Physiol Biochem; 2017; 44(6):2310-2321. PubMed ID: 29258061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An insight of novel pharmacological therapies in hypertrophic cardiomyopathy.
    Orenes-Piñero E; Hernández-Romero D; Jover E; de la Morena G; Valdés M; Marín F
    Med Chem; 2011 Jul; 7(4):275-85. PubMed ID: 21568880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A transgenic rabbit model for human hypertrophic cardiomyopathy.
    Marian AJ; Wu Y; Lim DS; McCluggage M; Youker K; Yu QT; Brugada R; DeMayo F; Quinones M; Roberts R
    J Clin Invest; 1999 Dec; 104(12):1683-92. PubMed ID: 10606622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
    Coppini R; Mazzoni L; Ferrantini C; Gentile F; Pioner JM; Laurino A; Santini L; Bargelli V; Rotellini M; Bartolucci G; Crocini C; Sacconi L; Tesi C; Belardinelli L; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Poggesi C
    Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28255011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy.
    Wilder T; Ryba DM; Wieczorek DF; Wolska BM; Solaro RJ
    Am J Physiol Heart Circ Physiol; 2015 Nov; 309(10):H1720-30. PubMed ID: 26432840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingosine-1-Phosphate Receptor Modulator, FTY720, Improves Diastolic Dysfunction and Partially Reverses Atrial Remodeling in a Tm-E180G Mouse Model Linked to Hypertrophic Cardiomyopathy.
    Ryba DM; Warren CM; Karam CN; Davis RT; Chowdhury SAK; Alvarez MG; McCann M; Liew CW; Wieczorek DF; Varga P; Solaro RJ; Wolska BM
    Circ Heart Fail; 2019 Nov; 12(11):e005835. PubMed ID: 31684756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.
    Marian AJ; Salek L; Lutucuta S
    Minerva Med; 2001 Dec; 92(6):435-51. PubMed ID: 11740432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.